Mercados españoles abiertos en 2 hrs

UCB SA (UCBJF)

OTC Markets OTCPK - OTC Markets OTCPK Precio demorado. Divisa en USD
Añadir a la lista de favoritos
152,500,00 (0,00%)
Al cierre: 04:00PM EDT

UCB SA

Allée de la Recherche, 60
Brussels 1070
Belgium
32 2 559 99 99
https://www.ucb.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo8450

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Jean-Christophe TellierCEO & Executive Director4,46MN/A1959
Ms. Sandrine Dufour CFAExecutive VP, CFO & Chief Corporate DevelopmentN/AN/A1966
Dr. Kirsten Lund-Jurgensen Ph.D.Executive Vice President of Supply & Technology SolutionsN/AN/A1960
Ms. Denelle J. Waynick Johnson J.D.Executive VP & General CounselN/AN/A1967
Mr. Jean-Luc FleurialExecutive VP & Chief Human Resources OfficerN/AN/A1965
Prof. Iris Loew-FriedrichExecutive VP & Chief Medical OfficerN/AN/A1960
Mr. Emmanuel CaeymaexExecutive VP & Chief Commercial OfficerN/AN/A1969
Ms. Fiona du MonceauExecutive Vice President of Patient Evidence178,6kN/A1978
Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsN/AN/AN/A
Mr. Alistair HenryExecutive VP & Chief Scientific OfficerN/AN/A1967
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Gobierno corporativo

El ISS Governance QualityScore de UCB SA, a día 1 de julio de 2024, es 1. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 1; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.